We can’t show the full text here under this license. Use the link below to read it at the source.
GLP ‐ 1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score Matching
GLP-1RA and Liver Scarring Progression in Fatty Liver Disease with Type 2 Diabetes Using Matched Patient Data
AI simplified
Abstract
GLP-1 receptor agonist (GLP-1RA) use was associated with a lower risk of liver fibrosis progression in patients with type 2 diabetes and early-stage metabolic dysfunction-associated steatotic liver disease.
- GLP-1RA users had an incidence rate of 3.25 per 100 person-years for fibrosis progression, compared to 4.29 for those using dipeptidyl peptidase-4 inhibitors (DPP-4i).
- The hazard ratio for fibrosis progression in GLP-1RA users was 0.75, indicating a 25% reduction in risk compared to DPP-4i users.
- Risk reduction with GLP-1RA was consistent across various subgroups, including those with low baseline fibrosis scores and lower body mass index.
- No significant differences in secondary liver-related outcomes were observed between GLP-1RA and DPP-4i users.
AI simplified
Key numbers
0.75
Decrease in Risk
Hazard ratio for vs. users.
3.25 per 100 person-years
Incidence Rate of
Compared to 4.29 per 100 person-years for users.